Skip to main content

Aclaris Therapts(ACRS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Aclaris Therapeutics Expands Leadership Team

Globe Newswire - Tue Feb 1, 2022

WAYNE, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of James Loerop as Chief Business Officer, effective January 31, 2022.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

opinion
Four reasons why wealthy investors should hold farmland in their portfolios
Andrea Gruza